Systematic Review

Association between genetic polymorphism and antidepressants in major depression: a network meta-analysis

Department of Psychiatry, Laboratory of Neurological Diseases & Brain Function, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

‡Authors contributed equally

Search for more papers by this author

Qiong Tang^‡

Department of Psychiatry, Laboratory of Neurological Diseases & Brain Function, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

‡Authors contributed equally

Search for more papers by this author

Qiong Han

Department of Breast Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

Search for more papers by this author

Jin Zhang

Department of Psychiatry, Laboratory of Neurological Diseases & Brain Function, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

Zigong Mental Health Research Center & Institute on Aging at Zigong, Zigong, 643020, Sichuan Province, China

Search for more papers by this author

Xuemei Liang

Geriatrics Department, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

Search for more papers by this author

Youguo Tan

Zigong Mental Health Center, Zigong, 643020, Sichuan Province, China

Zigong Mental Health Research Center & Institute on Aging at Zigong, Zigong, 643020, Sichuan Province, China

Search for more papers by this author

Kezhi Liu

*Author for correspondence:

E-mail Address: kingzliu@163.com

Department of Psychiatry, Laboratory of Neurological Diseases & Brain Function, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

Search for more papers by this author

Bo Xiang

**Author for correspondence:

E-mail Address: xiangbo@swmu.edu.cn

https://orcid.org/0000-0001-8341-2286

Department of Psychiatry, Laboratory of Neurological Diseases & Brain Function, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China

Zigong Mental Health Research Center & Institute on Aging at Zigong, Zigong, 643020, Sichuan Province, China

Search for more papers by this author

Published Online:21 Aug 2020https://doi.org/10.2217/pgs-2020-0037

View article

Abstract

This network meta-analysis was conducted to compare the predictive value of eight SNPs on the efficacy of antidepressants in major depressive disorder (MDD), including 5-HTTLPR, 5HTR2A (rs6311, rs6314, rs7997012 and rs6313), 5HTR2A (rs6295), BDNF (rs6265) and 5HTTSTin2. Databases were searched for related studies published up to December 2019. A total of 16 studies were included in this study. The predictive value were evaluated by the use of the odd ratios (OR) and drawing surface under the cumulative ranking curves (SUCRA). The pairwise meta-analysis indicated that in terms of overall response ratio, the SNPs were not associated with the efficacy of antidepressants in MDD. The result of this network meta-analysis suggested that there was no significant difference in predictive value of eight SNPs on the efficacy of antidepressants in MDD. More research is needed to explore the relationship between SNPs and antidepressant response.

Keywords:

References

1. Bromet E, Andrade LH, Hwang I et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 9, 90 (2011).
MedlineGoogle Scholar
2. Malhi GS, Mann JJ. Depression. Lancet 392(10161), 2299–2312 (2018).
MedlineGoogle Scholar
3. Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science 274(5288), 740–743 (1996).
Medline CASGoogle Scholar
4. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch. Gen. Psychiatry 60(9), 929–937 (2003).
MedlineGoogle Scholar
5. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128), 1357–1366 (2018).
Medline CASGoogle Scholar
6. Ozbey G, Celikel FC, Cumurcu BE et al. Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder. Nord. J. Psychiatry 71(3), 230–237 (2017).
MedlineGoogle Scholar
7. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 22(4), 239–258 (2012).
Medline CASGoogle Scholar
8. Kim H, Lim SW, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 296(13), 1609–1618 (2006).
Medline CASGoogle Scholar
9. Andre K, Kampman O, Viikki M et al. TPH1 A218C polymorphism and temperament in major depression. BMC Psychiatry 13, 118 (2013).
MedlineGoogle Scholar
10. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 88(1), 17–31 (2009).
Medline CASGoogle Scholar
11. Gasso P, Rodriguez N, Blazquez A et al. Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. Prog. Neuropsychopharmacol. Biol. Psychiatry 75, 28–34 (2017).
Medline CASGoogle Scholar
12. Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin Type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53(4), 186–195 (2006).
Medline CASGoogle Scholar
13. Illi A, Setala-Soikkeli E, Viikki M et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20(12), 1125–1128 (2009).
Medline CASGoogle Scholar
14. Maruf AA, Greenslade A, Arnold PD, Bousman C. Antidepressant pharmacogenetics in children and young adults: a systematic review. J. Affect. Disord. 254, 98–108 (2019).
Medline CASGoogle Scholar
15. Sahraian S, Babashams M, Reza-Soltani P, Najmabadi H, Kahrizi K, Gorgani SH. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness in Iranian patients with major depressive disorder. Iranian J. Psychiatry 8(2), 86–91 (2013).
MedlineGoogle Scholar
16. Zou YF, Ye DQ, Feng XL, Su H, Pan FM, Liao FF. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur. Neuropsychopharmacol. 20(8), 535–544 (2010).
Medline CASGoogle Scholar
17. Lohoff FW, Aquino TD, Narasimhan S, Multani PK, Etemad B, Rickels K. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J. 13(1), 21–26 (2013).
Medline CASGoogle Scholar
18. Singh AB, Bousman CA, Ng C, Berk M. Antidepressant pharmacogenetics. Curr. Opin. Psychiatry 27(1), 43–51 (2014).
MedlineGoogle Scholar
19. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 15(5), 473–500 (2010).
Medline CASGoogle Scholar
20. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol. Psychiatry 68(6), 536–543 (2010).
Medline CASGoogle Scholar
21. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 183–194 (2013).
Medline CASGoogle Scholar
22. Kao CF, Liu YL, Yu YW et al. Gene-based analysis of genes related to neurotrophic pathway suggests association of BDNF and VEGFA with antidepressant treatment-response in depressed patients. Sci. Rep. 8(1), 6983 (2018).
MedlineGoogle Scholar
23. Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using stata. Epidemiol. Health 39, e2017047 (2017).
MedlineGoogle Scholar
24. Bozina N, Peles AM, Sagud M, Bilusic H, Jakovljevic M. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J. Biol. Psychiatry 9(3), 190–197 (2008).
MedlineGoogle Scholar
25. Dogan O, Yuksel N, Ergun MA et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet. Test. 12(2), 225–231 (2008).
Medline CASGoogle Scholar
26. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 6(1), 27–33 (2006).
Medline CASGoogle Scholar
27. Noro M, Antonijevic I, Forray C et al. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int. Clin. Psychopharmacol. 25(4), 228–231 (2010).
MedlineGoogle Scholar
28. Matsumoto Y, Fabbri C, Pellegrini S et al. Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. Mol. Diagn. Ther. 18(5), 567–577 (2014).
Medline CASGoogle Scholar
29. Min W, Li T, Ma X et al. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology 205(3), 409–417 (2009).
Medline CASGoogle Scholar
30. Serretti A, Fabbri C, Pellegrini S et al. No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 10(2), 180–189 (2013).
MedlineGoogle Scholar
31. Wilkie MJ, Smith G, Day RK et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 9(1), 61–70 (2009).
Medline CASGoogle Scholar
32. Tatham EL, Hall GB, Clark D, Foster J, Ramasubbu R. The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression. Eur. Arch. Psychiatry Clin. Neurosci. 267(2), 135–147 (2017).
MedlineGoogle Scholar
33. Dong ZQ, Li XR, He L, He G, Yu T, Sun XL. 5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients. Neuropsychiatr. Dis. Treat. 12, 1623–1629 (2016).
Medline CASGoogle Scholar
34. Nishioka G, Yashima H, Kiuchi Y et al. Prediction and structural equation model of sertraline treatment response in Japanese patients with major depressive disorder. Human Psychopharmacol. 28(6), 576–585 (2013).
Medline CASGoogle Scholar
35. Basu A, Chadda RK, Sood M, Kaur H, Kukreti R. Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: a preliminary study. Indian J. Med. Res. 142(1), 40–45 (2015).
Medline CASGoogle Scholar
36. Kishi T, Yoshimura R, Kitajima T et al. HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med. 12(3), 237–242 (2010).
Medline CASGoogle Scholar
37. Lee SH, Choi TK, Lee E et al. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine. Neuropsychobiology 62(3), 198–206 (2010).
Medline CASGoogle Scholar
38. Mrazek DA, Rush AJ, Biernacka JM et al. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B(3), 341–351 (2009).
Medline CASGoogle Scholar
39. Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64(7), 783–792 (2007).
Medline CASGoogle Scholar
40. Kang HJ, Bae KY, Kim SW et al. BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome. J. Affect. Disord. 194, 1–8 (2016).
Medline CASGoogle Scholar
41. Lin JY, Jiang MY, Kan ZM, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J. Affect. Disord. 168, 430–438 (2014).
Medline CASGoogle Scholar
42. Antypa N, Calati R, Souery D et al. Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. J. Affect. Disord. 150(2), 649–652 (2013).
Medline CASGoogle Scholar
43. Zhou C, Zhong J, Zou B et al. Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression. PLoS ONE 12(2), e0172270 (2017).
MedlineGoogle Scholar
44. Mcmahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78(5), 804–814 (2006).
Medline CASGoogle Scholar
45. Gasso P, Blazquez A, Rodriguez N et al. Further support for the involvement of genetic variants related to the serotonergic pathway in the antidepressant response in children and adolescents after a 12-month follow-up: impact of the HTR2A rs7997012 polymorphism. J. Child Adolesc. Psychopharmacol. 28(10), 711–718 (2018).
Medline CASGoogle Scholar
46. Lin E, Chen PS, Chang HH et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(7), 1167–1172 (2009).
Medline CASGoogle Scholar
47. Brunoni AR, Carracedo A, Amigo OM et al. Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial. Braz. J. Psychiatry 42(2), 128–135 (2019).
MedlineGoogle Scholar
48. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican–Americans. Mol. Psychiatry 14(12), 1105–1118 (2009).
Medline CASGoogle Scholar

Vol. 21, No. 13

Supplemental Materials

Metrics

Downloaded 217 times

History

Received 17 March 2020

Accepted 19 May 2020

Published online 21 August 2020

Published in print August 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/pgs-2020-0037

Author contributions

B Xiang designed the study and wrote the protocol. D Du, Q Tang, J Zhang, X Liang, Y Tan and K Liu managed the literature searches and analyses. D Du and Q Han undertook the statistical analysis; D Du wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

Acknowledgments

The authors thank all co-workers.

Financial & competing interests disclosure

This study was supported in part by a grant from the Sichuan provincial health and Family Planning Commission (no. 18PJ310), Key projects of the Sichuan Provincial Education Department (no. 18ZA0534), Luzhou science and Technology Bureau (no. 2015LZCYD-S06 [5/11] and 2016-S-67 [7/23]) and the Southwest Medical University-Luzhou Government (no. 2016LZXNYD-T08 and 2017LZXNYD-Z02). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download